SCHEMBL7069716

SCHEMBL7069716

C[C@H](NC1=NSc2cnccc2N1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 2/20 0.42
MAPT P10636 1/20 0.41
IDO1 P14902 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LATS1 O95835 4/20 0.41
LATS2 Q9NRM7 1/20 0.39
LIMK1 P53667 2/20 0.38
ROCK1 Q13464 2/20 0.38
AURKB Q96GD4 2/20 0.38
ROCK2 O75116 2/20 0.38
JAK2 O60674 2/20 0.38
JAK3 P52333 2/20 0.38
DCLK1 O15075 1/20 0.38
CHEK2 O96017 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
IRAK1 P51617 1/20 0.38
PRKX P51817 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7068593 1.00 KDM4C (0.43) KDM4CKDM4EGAAMAPTIDO1
SCHEMBL7068588 1.00 KDM4C (0.43) KDM4CKDM4EGAAMAPTIDO1
SCHEMBL8582616 0.84 KDM4E (0.51) KDM4CKDM4EGAAMAPTIDO1
SCHEMBL7066158 0.79 LATS1 (0.39) GAAMAPTIDO1L3MBTL1LATS1
SCHEMBL8663744 0.79 TAAR1 (0.35) GAAMAPTROCK1AURKBROCK2
SCHEMBL8662956 0.79 TAAR1 (0.35) GAAMAPTROCK1AURKBROCK2
SCHEMBL8662959 0.79 TAAR1 (0.35) GAAMAPTROCK1AURKBROCK2
SCHEMBL8582578 0.79 HTT (0.37) MAPTPLK1CYP3A4CYP2C9MAPK1
SCHEMBL8582583 0.79 HTT (0.37) MAPTPLK1CYP3A4CYP2C9MAPK1
SCHEMBL8587279 0.79 HTT (0.37) MAPTPLK1CYP3A4CYP2C9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003105896-A1 COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND NOVO NORDISK A/S (DK) 2003-12-24 WO claimed
WO-2003045954-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 WO claimed
WO-2003045955-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 WO claimed
WO-2002000222-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER NOVO NORDISK A/S (DK) 2002-01-03 WO claimed
WO-2002000223-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION NOVO NORDISK A/S (DK) 2002-01-03 WO claimed
EP-0877748-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1998-11-18 EP claimed
WO-1997026264-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1997-07-24 WO claimed
WO-2003105896-A1 COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND NOVO NORDISK A/S (DK) 2003-12-24 WO disclosed
WO-2002000222-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER NOVO NORDISK A/S (DK) 2002-01-03 WO disclosed
WO-2002000223-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION NOVO NORDISK A/S (DK) 2002-01-03 WO disclosed
EP-0877748-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1998-11-18 EP disclosed
WO-1997026264-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1997-07-24 WO disclosed